Recap: Intersect ENT Q1 Earnings
Shares of Intersect ENT (NASDAQ:XENT) were unchanged at $13.49 after the company reported Q1 results.
Quarterly Results
Earnings per share decreased 54.29% year over year to ($0.54), which missed the estimate of ($0.44).
Revenue of $19,826,000 lower by 25.67% year over year, which missed the estimate of $23,660,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Intersect ENT hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: May 11, 2020
Time: 07:04 PM ET
Webcast URL: https://78449.choruscall.com/dataconf/productusers/xent/mediaframe/37432/indexr.html
Price Action
52-week high: $31.46
Company's 52-week low was at $5.97
Price action over last quarter: down 42.84%
Company Description
Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
